Scientists looking into a type of spinal cord injury have said their latest research represents a major step forward.
The Neuralstem staff are to conduct tests on amyotrophic lateral sclerosis (ALS), an ailment which leaves people paralyzed.
It has been given the green light by the US Food and Drug Administration to undertake the clinical trial, which is aimed at devising ways of slowing down an illness for which a cure has yet to be found.
Participants in the tests will have varying strains of the problem and will be injected with drugs in the lumbar area of the spinal cord.
Commenting, chief executive officer and president of Neuralstem Richard Garr said: "While this trial aims to primarily establish safety and feasibility data in treating ALS patients, we also hope to be able to measure a slowing down of the ALS degenerative process."
Another educational institution conducting ongoing tests in this area is the Boston University of Medicine.
Three American football players recently agreed to donate spinal cord and brain tissue to the centre upon their death.
Serious Law, leading spinal cord injury solicitors